NCT05782972View on ClinicalTrials.gov

Therapeutic Response of Sodium-glucose Co-transporter Type-2 Inhibitor in Non-diabetic MAFLD Patients: a Pilot Study

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 11, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions
Metabolic Associated Fatty Liver Disease
Interventions
DRUG

dapagliflozin (Forxiga)

The participants received oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks.

Trial Locations (1)

23142

Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City

All Listed Sponsors
lead

Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

OTHER